Your browser doesn't support javascript.
loading
Insensitivity to T790M mutation? A pooled analysis of outcomes following osimertinib for the treatment of NSCLC patients harboring uncommon epidermal growth factor receptor mutation.
Hu, Shanliang; Wang, Congjie; Wang, Chunsheng; Zhao, Kewei; Wang, Zhen; Dong, Wei.
Afiliação
  • Hu S; Department of Radiation Oncology, Yantai Yuhuangding Hospital, Yantai, China.
  • Wang C; Department of Pulmonary and Critical Care Medicine, Yantai Yuhuangding Hospital, Yantai, China.
  • Wang C; Department of Radiation Oncology, Yantai Yuhuangding Hospital, Yantai, China.
  • Zhao K; Department of Radiation & Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Wang Z; Department of Radiation Oncology, Yantai Yuhuangding Hospital, Yantai, China.
  • Dong W; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Pharmacol ; 13: 986962, 2022.
Article em En | MEDLINE | ID: mdl-36091840
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article